Cardiff Oncology (CRDF) 10-Q 7 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 31, 2018
Document and Entity Information
Entity Registrant Name	Trovagene, Inc.
Entity Central Index Key	1,213,037
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		22,990,942
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 15,065,913	$ 8,225,764
Accounts receivable and unbilled receivable	128,577	77,095
Prepaid expenses and other current assets	849,082	1,165,828
Total current assets	16,043,572	9,468,687
Property and equipment, net	1,627,605	2,426,312
Other assets	249,645	389,942
Total Assets	17,920,822	12,284,941
Current liabilities:
Accounts payable	476,300	825,244
Accrued expenses	1,718,060	1,454,587
Deferred rent, current portion	472,251	334,424
Current portion of long-term debt	0	1,331,515
Total current liabilities	2,666,611	3,945,770
Derivative financial instruments—warrants	70,347	649,387
Deferred rent, net of current portion	1,204,109	1,183,677
Total Liabilities	3,941,067	5,778,834
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 277,100 designated as Series A Convertible Preferred Stock; 60,600 shares outstanding at September 30, 2018 and December 31, 2017 with liquidation preference of $606,000 at September 30, 2018 and December 31, 2017; 8,860 designated as Series B Convertible Preferred Stock; 0 shares outstanding at September 30, 2018 and December 31, 2017, respectively	60	60
Common stock, $0.0001 par value, 150,000,000 shares authorized; 22,957,192 and 4,399,299 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	7,738	5,279
Additional paid-in capital	201,998,634	179,546,954
Accumulated deficit	(188,026,677)	(173,046,186)
Total stockholders’ equity	13,979,755	6,506,107
Total liabilities and stockholders’ equity	$ 17,920,822	$ 12,284,941

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in USD per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	22,957,192	4,399,299
Common stock, shares outstanding (in shares)	22,957,192	4,399,299
Series A Convertible Preferred Stock
Preferred stock, shares authorized (in shares)	277,100	277,100
Preferred stock, shares outstanding (in shares)	60,600	60,600
Series A Convertible Preferred Stock, liquidation preference (in dollars)	$ 606,000	$ 606,000
Series B Convertible Preferred Stock
Preferred stock, shares authorized (in shares)	8,860	8,860
Preferred stock, shares outstanding (in shares)	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Royalties	$ 72,568	$ 58,779	$ 174,046	$ 169,415
Diagnostic services	4,303	58,119	83,650	142,482
Clinical research services	11,490	6,431	42,614	8,481
Total revenues	88,361	123,329	300,310	320,378
Costs and expenses:
Cost of revenues	26,677	473,202	597,457	1,427,831
Research and development	1,830,441	1,414,706	5,667,046	6,676,251
Selling, general and administrative	1,665,200	4,079,514	6,321,048	12,358,290
Restructuring charges (benefit)	421,351	(46,472)	664,686	1,669,526
Total operating expenses	3,943,669	5,920,950	13,250,237	22,131,898
Loss from operations	(3,855,308)	(5,797,621)	(12,949,927)	(21,811,520)
Interest income	85,938	20,650	143,911	132,515
Interest expense	(16)	(37,123)	(25,177)	(1,010,256)
(Loss) gain from change in fair value of derivative financial instruments—warrants	(2,500)	1,528,669	579,040	2,012,747
Gain (loss) on extinguishment of debt	0	0	17,974	(1,655,825)
Other income (loss), net	2,318	(6,541)	(68,521)	(4,975)
Net loss	(3,769,568)	(4,291,966)	(12,302,700)	(22,337,314)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(6,060)	(6,060)	(18,180)	(18,180)
Deemed dividend recognized for beneficial conversion features of Series B Convertible Preferred Stock issuance	0	0	2,769,533	0
Net loss attributable to common stockholders	$ (3,775,628)	$ (4,298,026)	$ (15,090,413)	$ (22,355,494)
Net loss per common share - basic (in USD per share)	$ (0.18)	$ (1.41)	$ (1.38)	$ (8.17)
Net loss per common share - diluted (in USD per share)	$ (0.18)	$ (1.41)	$ (1.38)	$ (8.17)
Weighted-average shares outstanding — basic (in shares)	20,622,660	3,038,806	10,945,249	2,735,526
Weighted-average shares outstanding — diluted (in shares)	20,622,660	3,038,806	10,945,249	2,735,526

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statement - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Net loss	$ (3,769,568)	$ (4,291,966)	$ (12,302,700)	$ (22,337,314)
Other comprehensive income (loss):
Foreign currency translation loss	0	(1,544)	0	(13,486)
Unrealized gain or reversal of previous losses on securities available-for-sale	0	0	0	9,065
Total other comprehensive loss	0	(1,544)	0	(4,421)
Total comprehensive loss	(3,769,568)	(4,293,510)	(12,302,700)	(22,341,735)
Preferred stock dividend payable on Series A Convertible Preferred Stock	6,060	6,060	18,180	18,180
Deemed dividend recognized for beneficial conversion features of Series B Convertible Preferred Stock issuance	0	0	2,769,533	0
Comprehensive loss attributable to common stockholders	$ (3,775,628)	$ (4,299,570)	$ (15,090,413)	$ (22,359,915)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities
Net loss	$ (12,302,700)	$ (22,337,314)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of assets	197,490	28,199
Impairment loss	187,500	485,000
Depreciation and amortization	701,774	956,995
Stock based compensation expense	1,905,652	3,117,364
(Gain) loss on extinguishment of debt	(17,974)	1,655,825
Accretion of final fee premium	0	293,614
Amortization of discount on debt	0	113,780
Net realized loss on short-term investments	0	6,400
Amortization of premiums on short-term investments	0	9,230
Deferred rent	(266,556)	(207,435)
Interest income accrued on short-term investments	0	(90,330)
Change in fair value of derivative financial instruments—warrants	(579,040)	(2,012,747)
Changes in operating assets and liabilities:
Increase in other assets	(170,602)	0
Decrease (increase) in accounts receivable and unbilled receivable	58,440	(77,667)
Decrease in prepaid expenses and other current assets	316,746	18,230
Increase (decrease) in accounts payable and accrued expenses	383,037	(1,908,796)
Net cash used in operating activities	(9,586,233)	(19,949,652)
Investing activities:
Proceeds from disposals of capital equipment	27,942	0
Capital expenditures	(5,100)	(136,251)
Maturities of short-term investments	0	16,431,837
Purchases of short-term investments	(31,500)	(8,804,604)
Sales of short-term investments	31,500	16,434,553
Net cash provided by investing activities	22,842	23,925,535
Financing activities:
Proceeds from sales of common stock and warrants, net of expenses of $1,336,123 and $575,516, respectively	11,779,525	6,634,803
Proceeds from sales of Series B Convertible Preferred Stock, net of expenses of $497,617	4,386,762	0
Proceeds from exercise of warrants	1,612,667	0
Payment upon debt extinguishment	(175,381)	(1,613,067)
Repayments of long-term debt	0	(15,000,000)
Repayments of equipment line of credit	(1,200,033)	(469,578)
Net cash provided by (used in) financing activities	16,403,540	(10,447,842)
Effect of exchange rate changes on cash and cash equivalents	0	(8,837)
Net change in cash and cash equivalents	6,840,149	(6,480,796)
Cash and cash equivalents—Beginning of period	8,225,764	13,915,094
Cash and cash equivalents—End of period	15,065,913	7,434,298
Supplementary disclosure of cash flow activity:
Cash paid for taxes	800	800
Cash paid for interest	22,482	650,331
Supplemental disclosure of non-cash investing and financing activities:
Preferred stock dividend payable on Series A Convertible Preferred Stock	18,180	18,180
Deemed dividend recognized for beneficial conversion features of Series B Convertible Preferred Stock issuance	2,769,533	0
Common stock issued upon conversion of Series B Convertible Preferred Stock	$ 886	$ 0

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Common stock and warrants
Payments of stock issuance costs	$ (1,336,123)	$ (575,516)
Series B Convertible Preferred Stock
Payments of stock issuance costs	$ (497,617)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statement - 9 months ended Sep. 30, 2018 - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, January 1, 2018 (in shares) at Dec. 31, 2017		60,600	4,399,299
Balance, January 1, 2018 at Dec. 31, 2017	$ 6,506,107	$ 60	$ 5,279	$ 179,546,954	$ (173,046,186)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	1,905,652			1,905,652
Sale of common stock and warrants, net of expenses ( in shares)			9,140,000
Sale of common stock and warrants, net of expenses	11,779,525		$ 914	11,778,611
Sale of Series B Convertible Preferred Stock, net of expenses (in shares)		8,860	18,557,893
Sale of Series B Convertible Preferred Stock, net of expenses	4,386,762	$ 9		4,386,753
Beneficial Conversion Feature For Issuance Of Series B Convertible Preferred Stock				(2,769,533)	2,769,533
Issuance of common stock upon exercise of warrants (in shares)			473,497
Issuance of common stock upon exercise of warrants			$ 569	1,612,098
Issuance of common stock upon exercise of warrants, net	1,612,667
Issuance of common stock upon vesting of restricted stock units (in shares)			77,572
Issuance of common stock upon vesting of restricted stock units			$ 90	(90)
Stock Issued During Period, Shares, Conversion of Convertible Securities		8,860	8,860,000
Issuance of common stock upon conversion of Series B Convertible Preferred Stock		$ (9)	$ 886	(877)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(18,180)				(18,180)
Issuance of common stock for share rounding as a result of reverse stock split (in shares)			6,824
Cumulative adjustment upon adoption of ASC 606	109,922				109,922
Net loss	(12,302,700)				(12,302,700)
Balance, September 30, 2018 (in shares) at Sep. 30, 2018		60,600	22,957,192
Balance, September 30, 2018 at Sep. 30, 2018	$ 13,979,755	$ 60	$ 7,738	$ 201,998,634	$ (188,026,677)

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Business Organization and Overview Trovagene, Inc. (“Trovagene” or the “Company”) headquartered in San Diego, California, is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene’s intellectual property and proprietary technology enables the Company to analyze circulating tumor DNA (“ctDNA”) and clinically actionable markers. Unique to the Company’s clinical development plan, and a key component of its precision cancer medicine approach, is the integration of predictive clinical biomarkers to identify patients most likely to respond to treatment. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of Trovagene, which include all accounts of its wholly owned subsidiary, Trovagene, Srl (dissolved in October 2017), have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The unaudited interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December 31, 2017 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2017 included in the Company’s annual report on Form 10-K filed with the SEC on February 26, 2018. The Company made a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 12 , effective June 1, 2018. All share and per share information in the unaudited condensed consolidated financial statements and the accompanying notes have been retroactively adjusted to reflect the reverse stock split for all periods presented. Liquidity Trovagene’s condensed consolidated financial statements as of September 30, 2018 have been prepared under the assumption that Trovagene will continue as a going concern, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern. The Company has incurred net losses since its inception and has negative operating cash flows. Considering the Company’s current cash resources, including the net proceeds received from the offering of its equity securities in June 2018, management believes the Company’s existing resources will be sufficient to fund the Company’s planned operations through July 2019. On April 6, 2018, the Company paid off the outstanding Loan and Security Agreement (“Equipment Line of Credit”) entered in November 2015 to Silicon Valley Bank (“SVB”). Based on its current business plan and assumptions, the Company expects to continue to incur significant losses and require significant additional capital to further advance its clinical trial programs and support its other operations. The Company has based its cash sufficiency estimates on its current business plan and its assumptions that may prove to be wrong. The Company could utilize its available capital resources sooner than it currently expects, and it could need additional funding to sustain its operations even sooner than currently anticipated. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates, all of which would have a material adverse impact on the Company’s operations. The Company may also be required to: • Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and • Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms. The Company is evaluating the following options to raise additional capital, increase revenue, as well as reduce costs, in an effort to strengthen its liquidity position: • Raising capital through public and private equity offerings; • Introducing operation and business development initiatives to bring in new revenue streams; • Reducing operating costs by identifying internal synergies; and • Engaging in strategic partnerships. As of October 31, 2018, the Company has received approximately $1.6 million upon exercise of 5,681,667 warrants in connection with the December 2017 public offering. The Company continually assesses its spending plans to effectively and efficiently address its liquidity needs. NASDAQ Notice On September 5, 2017, the Company received a written notice from the NASDAQ Stock Market LLC (“NASDAQ”) that it was not in compliance with NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market, as the minimum bid price of the Company’s common stock had been below $1.00 per share for 30 consecutive business days. In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company had a period of 180 calendar days, or until March 5, 2018, to regain compliance with the minimum bid price requirement. On March 6, 2018, the NASDAQ Capital Market informed the Company that it is eligible for an additional 180 calendar day period until September 4, 2018 to regain compliance with the minimum $1.00 bid price per share requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180 calendar day period. On September 7, 2018, the Company received a letter from NASDAQ indicating that, based upon the Company’s continued non-compliance with the Minimum Bid Price Rule, the Company’s common stock would be subject to delisting unless the Company timely requests a hearing before a NASDAQ Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel on September 14, 2018, which request will stay any further action by NASDAQ at least pending the issuance of a decision following the hearing and the expiration of any additional extension that may be granted by the Panel. The Company is scheduled to attend the hearing before the Panel on November 8, 2018. The Company is considering all of its options to regain compliance; however, there can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to evidence compliance with the continued listing criteria within the period of time that the Panel may grant it to do so.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies During the nine months ended September 30, 2018 , there have been no changes to the Company’s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017 , except as described below. Revenue Recognition The Company recognizes revenue when control of its products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: • Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. • Minimum royalties are recognized as earned, and royalties are earned based on the licensee’s use. The Company estimates and records licensee’s sales based on historical usage rate and collectability. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. This revenue stream does not meet the criteria for contracts with a customer under ASC 606 because it is not probable that the Company will collect substantially all the consideration to which it will be entitled in exchange for the goods and services transferred, nor can it reliably determine the expected transaction price. Therefore, the Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements. As a result of disposition of the its Clinical Laboratory Improvement Amendments (“CLIA”) - certified laboratory, this revenue stream is declining and overall insignificant to the Company. Clinical Research Revenue Revenue from clinical research consists of revenue from the sale of urine and blood collection supplies and tests performed under agreements with our clinical research and business development partners. Revenue is recognized when supplies and/or test results are delivered, which is when control of the product is deemed to be transferred. Restructuring Restructuring costs are included in loss from operations in the consolidated statements of operations. The Company has accounted for these costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations . One-time termination benefits are recorded at the time they are communicated to the affected employees. In March 2017, the Company announced a restructuring plan which was completed as of December 31, 2017. In May 2018, the Company closed its CLIA laboratory operations. Costs associated with winding down the CLIA laboratory were recorded in the restructuring cost in the September 30, 2018 financial statements. See Note 9 to the consolidated financial statements for further information. Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share , for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. The following table sets forth the computation of basic and diluted earnings per share: Three Months Nine Months 2018 2017 2018 2017 Numerator: Net loss attributable to common shareholders $ (3,775,628 ) $ (4,298,026 ) $ (15,090,413 ) $ (22,355,494 ) Adjustment for gain from change in fair value of derivative financial instruments — warrants — — — — Net loss used for diluted loss per share $ (3,775,628 ) $ (4,298,026 ) $ (15,090,413 ) $ (22,355,494 ) Denominator for basic and diluted net loss per share: Weighted-average shares used to compute basic loss per share 20,622,660 3,038,806 10,945,249 2,735,526 Adjustments to reflect assumed exercise of warrants — — — — Weighted-average shares used to compute diluted net loss per share 20,622,660 3,038,806 10,945,249 2,735,526 Net loss per share attributable to common stockholders: Basic $ (0.18 ) $ (1.41 ) $ (1.38 ) $ (8.17 ) Diluted $ (0.18 ) $ (1.41 ) $ (1.38 ) $ (8.17 ) The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive: September 30, 2018 2017 Options to purchase Common Stock 500,246 354,753 Warrants to purchase Common Stock 22,189,533 747,709 Restricted Stock Units 214,872 106,442 Series A Convertible Preferred Stock 5,261 5,261 22,909,912 1,214,165 Recently Adopted Accounting Pronouncement In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which amends the FASB Accounting Standards Codification in order to simplify the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU 2018-07, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. The guidance mandates the modified retrospective approach and is effective for annual and interim reporting periods beginning after December 31, 2018, with early adoption permitted. The Company elected to early adopt this ASU 2018-07 as of September 30, 2018 and the adoption did not have an impact on the Company’s consolidated financial statements. Recent Accounting Pronouncement Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 changes accounting for leases and requires lessees to recognize the assets and liabilities arising from most leases, including those classified as operating leases under previous accounting guidance, on the balance sheet and requires disclosure of key information about leasing arrangements to increase transparency and comparability among organizations. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842 , which provides narrow amendments to clarify how to apply certain aspects of the new lease standard. In July 2018, ASU 2018-11, Leases: Targeted Improvements , was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The new guidance will be effective for the Company starting in the first quarter of fiscal year 2019. The new standards will impact the Company’s accounting for its equipment and office leases and the Company is currently evaluating the impact of the new standards on its consolidated financial statements and processes.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2018 and December 31, 2017 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 14,974,256 $ — $ — $ 14,974,256 Total Assets $ 14,974,256 $ — $ — $ 14,974,256 Liabilities: Derivative financial instruments — warrants $ — $ — $ 70,347 $ 70,347 Total Liabilities $ — $ — $ 70,347 $ 70,347 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 8,309,964 $ — $ — $ 8,309,964 Total Assets $ 8,309,964 $ — $ — $ 8,309,964 Liabilities: Derivative financial instruments — warrants $ — $ — $ 649,387 $ 649,387 Total Liabilities $ — $ — $ 649,387 $ 649,387 (1) Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets. The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2018 : Description Balance at Realized (gains) or losses Balance at Derivative financial instruments — warrants $ 649,387 $ (579,040 ) $ 70,347 The change in the fair value of the “derivative financial instruments—warrants” is recorded as a gain or loss in the Company’s consolidated statement of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40 and ASC Topic 480-10. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: As of September 30, As of December 31, Furniture and office equipment $ 1,072,156 $ 1,076,709 Leasehold improvements 1,994,514 1,994,514 Laboratory equipment 912,940 1,426,581 3,979,610 4,497,804 Less—accumulated depreciation and amortization (2,352,005 ) (2,071,492 ) Property and equipment, net $ 1,627,605 $ 2,426,312

Equipment Line of Credit

Equipment Line of Credit	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Equipment Line of Credit	Equipment Line of Credit In November 2015, the Company entered into a Loan and Security Agreement (“Equipment Line of Credit”) with SVB that provided for cash borrowings for equipment (“Equipment Advances”) of up to $2.0 million , secured by the equipment financed. Under the terms of the agreement, interest is equal to 1.25% above the Prime Rate. Interest only payments were due on borrowings through November 30, 2016, with both interest and principal payments commencing in December 2016. All unpaid principal and interest on each Equipment Advance will be due on November 1, 2019. The Company has an obligation to make a final payment equal to 7% of total amounts borrowed at the loan maturity date. The Company is also subject to certain affirmative and negative covenants under the Equipment Line of Credit. On June 20, 2017, the Company received a Notice of Event of Default (“Default Letter”) from SVB which stated that Events of Default had occurred and SVB will decide in its sole discretion whether or not to exercise rights and remedies. On April 6, 2018, the Company paid approximately $1,100,000 to SVB. This payment repaid the outstanding Equipment Line of Credit loan in full. The Company recorded $25,161 in interest expense related to the Equipment Line of Credit during the nine months ended September 30, 2018 .

Derivative Financial Instrument

Derivative Financial Instruments - Warrants	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments - Warrants	Derivative Financial Instruments — Warrants Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”) or ASC Topic 480-10, Distinguishing Liabilities from Equity (“ASC 480-10”), Trovagene determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities. In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s condensed consolidated statements of operations. The Company estimates the fair value of these warrants using the Black-Scholes option pricing model. The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was: Nine Months Ended September 30, 2018 2017 Estimated fair value of Trovagene common stock 0.77-4.20 8.76-15.12 Expected warrant term 0.3-5.1 years 1.3-5.5 years Risk-free interest rate 1.76-2.92% 1.27-1.95% Expected volatility 47-131% 86-109% Dividend yield 0 % 0 % Expected volatility is based on historical volatility of Trovagene’s common stock. The warrants have a transferability provision and based on guidance provided in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment (“SAB No. 107”) , for instruments issued with such a provision, Trovagene used the remaining contractual term as the expected term of the warrants. The risk-free rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date. The following table sets forth the components of changes in the Company’s derivative financial instruments — warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2017 Balance of derivative financial instruments — warrants liability 467,584 $ 649,387 Change in fair value of derivative financial instruments — warrants during the period recognized as a gain in the condensed consolidated statements of operations — (579,040 ) September 30, 2018 Balance of derivative financial instruments — warrants liability 467,584 $ 70,347

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Common Stock During the nine months ended September 30, 2018 , the Company issued a total of 18,557,893 shares of Common Stock. The Company received gross proceeds of approximately $18.0 million from the sale of 9,140,000 shares of its common stock, 20,700,000 warrants, and 8,860 shares of Series B Convertible Preferred Stock through an underwritten public offering in June 2018. 473,497 shares were issued upon exercise of warrants for a weighted-average price of $3.41 . 77,572 shares were issued upon vesting of restricted stock units (“RSUs”) and 8,860,000 shares were issued upon conversion of 8,860 shares of Series B Convertible Preferred Stock. In addition, 6,824 shares were issued for share rounding as a result of the reverse stock split. Stock Options Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Included in research and development expense $ 130,300 $ 219,480 $ 637,821 $ 798,143 Included in cost of revenue — 15,633 30,488 56,998 Included in selling, general and administrative expense 147,921 1,186,067 1,237,343 2,387,445 Benefit from restructuring — — — (125,222 ) Total stock-based compensation expense $ 278,221 $ 1,421,180 $ 1,905,652 $ 3,117,364 The unrecognized compensation cost related to non-vested stock options outstanding at September 30, 2018 and 2017 , net of expected forfeitures, was $499,861 and $3,271,046 , respectively, which is expected to be recognized over a weighted-average remaining vesting period of 1.3 and 2.2 years , respectively. The weighted-average remaining contractual term of outstanding options as of September 30, 2018 was approximately 7.6 years . The total fair value of stock options vested during the nine months ended September 30, 2018 and 2017 was $1,515,946 and $3,378,243 , respectively. The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated: Nine Months Ended September 30, 2018 2017 Risk-free interest rate 2.5 % 1.82 % Dividend yield 0 % 0 % Expected volatility 91 % 87 % Expected term 5.2 years 5.2 years A summary of stock option activity and changes in stock options outstanding is presented below: Total Options Weighted-Average Exercise Price Per Share Intrinsic Value Balance outstanding, December 31, 2017 374,251 $ 48.52 $ — Granted 316,744 $ 3.12 Canceled / Forfeited (189,540 ) $ 36.50 Expired (1,209 ) $ 36.00 Balance outstanding, September 30, 2018 500,246 $ 24.35 $ 3,370 Exercisable at September 30, 2018 355,696 $ 30.21 $ 1,950 On May 30, 2018, the number of authorized shares in the Trovagene 2014 Equity Incentive Plan (“2014 EIP”) was increased from 791,667 to 1,458,334 . As of September 30, 2018 there were 637,798 shares available for issuance under the 2014 EIP. Restricted Stock Units The weighted-average grant date fair value of the RSUs was $0.77 and $19.08 per share during the nine months ended September 30, 2018 and 2017 , respectively. A summary of the RSU activity is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Share Intrinsic Value Non-vested RSUs outstanding, December 31, 2017 106,200 $ 17.22 $ 391,878 Granted 204,750 $ 0.77 Vested (77,572 ) $ 13.83 $ 268,151 Forfeited (18,506 ) $ 24.60 Non-vested RSUs outstanding, September 30, 2018 214,872 $ 2.14 $ 175,121 At September 30, 2018 and 2017 , total unrecognized compensation cost related to non-vested RSUs were $263,695 and $1,011,494 , which are expected to be recognized over a weighted-average period of 2.0 and 2.5 years , respectively. The total fair value of vested RSUs during the nine months ended September 30, 2018 and 2017 were $1,072,714 and $1,285,578 , respectively. Warrants A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below: Total Warrants (1) Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (1) Balance outstanding, December 31, 2017 1,936,641 $ 11.34 4.4 Granted 20,700,000 $ 1.10 Exercised (447,108 ) $ 3.60 Balance outstanding, September 30, 2018 22,189,533 $ 1.94 4.6 (1) Excluded the pre-funded warrants to purchase 26,389 shares of common stock at a nominal exercise price of $0.12 per share. The pre-funded warrants were exercised in full during the nine months ended September 30, 2018 . Series B Convertible Preferred Stock On June 12, 2018, the Company closed an underwritten public offering for total gross proceeds of $18.0 million . The total related offering costs were approximately $1.8 million . The securities offered by the Company consisted of (i) 9,140,000 shares of common stock, at an offering price of $1.00 per share, (ii) warrants to purchase an aggregate of 20,700,000 shares of common stock, including the over-allotment option for 2,700,000 option warrants, at an exercise price of $1.10 per share, and (iii) 8,860 shares of Series B Convertible Preferred Stock, with a stated value of $1,000 , and convertible into an aggregate of 8,860,000 shares of common stock. The conversion feature of the Series B Convertible Preferred Stock at the time of issuance was determined to be beneficial on commitment date. Because the Series B Convertible Preferred Stock is perpetual with no stated maturity date, and the conversions may occur any time from inception, the Company immediately recorded a one-time, non-cash deemed dividend of $2.8 million related to the beneficial conversion feature arising from the issuance of Series B Convertible Preferred Stock. This one-time, non-cash deemed dividend increased the Company’s net loss attributable to common stockholders and net loss per share. The holders of Series B Convertible Preferred Stock are entitled to receive dividends on an as-if-converted-to-Common-Stock basis when, as and if such dividends are paid on shares of the Common Stock. Each share of Series B Convertible Preferred Stock shall entitle the holder to vote on an as-if-converted-to-Common-Stock basis (not exceeding the Beneficial Ownership Limitation). Upon any liquidation, dissolution or winding-up of the Company, the holders of Series B Convertible Preferred Stock are entitled to participate on an as-if-converted-to-Common Stock basis (without giving effect to the Beneficial Ownership Limitation) with holders of the Common Stock in any distribution of assets of the Company. Each share of Series B Convertible Preferred Stock is convertible at the option of the holder into that number of shares of Common Stock determined by dividing the stated value of $1,000 per share, by the conversion price of $1.00 per share. As of September 30, 2018 , there were no shares of Series B Convertible Preferred Stock outstanding.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Executive and Consulting Agreements The Company has longer-term contractual commitments with various consultants and employees. Certain employment agreements provide for severance payments. Lease Agreements The Company leases approximately 26,100 square feet of office and laboratory space at a monthly rental rate of approximately $73,000 . The lease will expire on December 31, 2021. The Company currently subleases certain office space and records the rental receipt under the subleases as a reduction of its rent expense. Research and Development and Clinical Trial Agreements In March 2017, the Company entered into a license agreement with Nerviano Medical Sciences S.r.l. (“Nerviano”) which granted the Company development and commercialization rights to NMS-1286937, which Trovagene refers to as onvansertib. Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK 1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $2.0 million in license fees which were expensed to research and development costs. Under the agreement, the Company is committed to pay $1.0 million for services provided by Nerviano, such as the costs to manufacture drug product, no later than June 30, 2019. As of September 30, 2018 , approximately $368,000 has been paid for services provided. Terms of the agreement also provide for the Company to pay royalties based on certain development and sales milestones. The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. To date, payments have not been material. Litigation Trovagene does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company’s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company’s business or financial condition.

Restructuring Charges

Restructuring Charges	9 Months Ended
	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring Charges In May 2018, the Company closed its CLIA laboratory operations in order to streamline the Company’s business model. The loss recognized from disposition of CLIA laboratory was reported as restructuring charges, a component of operating loss, in the condensed consolidated financial statements. During the nine months ended September 30, 2018, the Company recorded total restructuring charges of approximately $664,000 for CLIA laboratory disposal transactions, of which, approximately $187,000 was related to impairment loss on CLIA laboratory license, approximately $52,000 was related to loss on disposal of property and equipment and other non-capital assets, and approximately $425,000 was related to loss on sublease of office and laboratory space. In March 2017, the Company announced a strategic restructuring plan in connection with the expansion of precision medicine therapeutics to its business. The restructuring plan included a reduction in force and was completed in the last quarter of 2017. Restructuring charges of approximately $1.7 million were incurred and have been included as a component of operating loss for the nine months ended September 30, 2017. Of the total restructuring charges, approximately $1.2 million was related to termination of employees and an approximately $0.5 million charge related to impaired license fees.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Event Subsequent to the quarter end, the Company entered into an arrangement with Leucadia Life Sciences (“Leucadia”) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for AML. The cost of the services under the arrangement are expected to be up to $575,000 . The Company’s Interim Chief Executive Officer (“CEO”), Dr. Thomas Adams, is a principal stockholder of Leucadia. In addition, in connection with the arrangement, the Company may enter into a consulting agreement with Tommy Adams, VP of Operations of Leucadia, who is the son of Dr. Adams.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue when control of its products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: • Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. • Minimum royalties are recognized as earned, and royalties are earned based on the licensee’s use. The Company estimates and records licensee’s sales based on historical usage rate and collectability. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. This revenue stream does not meet the criteria for contracts with a customer under ASC 606 because it is not probable that the Company will collect substantially all the consideration to which it will be entitled in exchange for the goods and services transferred, nor can it reliably determine the expected transaction price. Therefore, the Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements. As a result of disposition of the its Clinical Laboratory Improvement Amendments (“CLIA”) - certified laboratory, this revenue stream is declining and overall insignificant to the Company. Clinical Research Revenue Revenue from clinical research consists of revenue from the sale of urine and blood collection supplies and tests performed under agreements with our clinical research and business development partners. Revenue is recognized when supplies and/or test results are delivered, which is when control of the product is deemed to be transferred.
Restructuring	Restructuring Restructuring costs are included in loss from operations in the consolidated statements of operations. The Company has accounted for these costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations . One-time termination benefits are recorded at the time they are communicated to the affected employees. In March 2017, the Company announced a restructuring plan which was completed as of December 31, 2017. In May 2018, the Company closed its CLIA laboratory operations. Costs associated with winding down the CLIA laboratory were recorded in the restructuring cost in the September 30, 2018 financial statements. See Note 9 to the consolidated financial statements for further information.
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share , for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive.
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncement In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which amends the FASB Accounting Standards Codification in order to simplify the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU 2018-07, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. The guidance mandates the modified retrospective approach and is effective for annual and interim reporting periods beginning after December 31, 2018, with early adoption permitted. The Company elected to early adopt this ASU 2018-07 as of September 30, 2018 and the adoption did not have an impact on the Company’s consolidated financial statements. Recent Accounting Pronouncement Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 changes accounting for leases and requires lessees to recognize the assets and liabilities arising from most leases, including those classified as operating leases under previous accounting guidance, on the balance sheet and requires disclosure of key information about leasing arrangements to increase transparency and comparability among organizations. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842 , which provides narrow amendments to clarify how to apply certain aspects of the new lease standard. In July 2018, ASU 2018-11, Leases: Targeted Improvements , was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The new guidance will be effective for the Company starting in the first quarter of fiscal year 2019. The new standards will impact the Company’s accounting for its equipment and office leases and the Company is currently evaluating the impact of the new standards on its consolidated financial statements and processes.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of Computation of Basic and Diluted Earnings per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Nine Months 2018 2017 2018 2017 Numerator: Net loss attributable to common shareholders $ (3,775,628 ) $ (4,298,026 ) $ (15,090,413 ) $ (22,355,494 ) Adjustment for gain from change in fair value of derivative financial instruments — warrants — — — — Net loss used for diluted loss per share $ (3,775,628 ) $ (4,298,026 ) $ (15,090,413 ) $ (22,355,494 ) Denominator for basic and diluted net loss per share: Weighted-average shares used to compute basic loss per share 20,622,660 3,038,806 10,945,249 2,735,526 Adjustments to reflect assumed exercise of warrants — — — — Weighted-average shares used to compute diluted net loss per share 20,622,660 3,038,806 10,945,249 2,735,526 Net loss per share attributable to common stockholders: Basic $ (0.18 ) $ (1.41 ) $ (1.38 ) $ (8.17 ) Diluted $ (0.18 ) $ (1.41 ) $ (1.38 ) $ (8.17 )
Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive: September 30, 2018 2017 Options to purchase Common Stock 500,246 354,753 Warrants to purchase Common Stock 22,189,533 747,709 Restricted Stock Units 214,872 106,442 Series A Convertible Preferred Stock 5,261 5,261 22,909,912 1,214,165

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of the Company’s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy	The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2018 and December 31, 2017 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 14,974,256 $ — $ — $ 14,974,256 Total Assets $ 14,974,256 $ — $ — $ 14,974,256 Liabilities: Derivative financial instruments — warrants $ — $ — $ 70,347 $ 70,347 Total Liabilities $ — $ — $ 70,347 $ 70,347 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 8,309,964 $ — $ — $ 8,309,964 Total Assets $ 8,309,964 $ — $ — $ 8,309,964 Liabilities: Derivative financial instruments — warrants $ — $ — $ 649,387 $ 649,387 Total Liabilities $ — $ — $ 649,387 $ 649,387 (1) Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets.
Schedule of Changes in the Fair Value of the Company’s Level 3 Liabilities	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2018 : Description Balance at Realized (gains) or losses Balance at Derivative financial instruments — warrants $ 649,387 $ (579,040 ) $ 70,347

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Schedule of Components of Property and Equipment	Property and equipment consist of the following: As of September 30, As of December 31, Furniture and office equipment $ 1,072,156 $ 1,076,709 Leasehold improvements 1,994,514 1,994,514 Laboratory equipment 912,940 1,426,581 3,979,610 4,497,804 Less—accumulated depreciation and amortization (2,352,005 ) (2,071,492 ) Property and equipment, net $ 1,627,605 $ 2,426,312

Derivative Financial Instrume_2

Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method	9 Months Ended
	Sep. 30, 2018
Derivative financial instruments
Schedule of Assumptions Used to Determine the Fair Value of the Warrants	The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was: Nine Months Ended September 30, 2018 2017 Estimated fair value of Trovagene common stock 0.77-4.20 8.76-15.12 Expected warrant term 0.3-5.1 years 1.3-5.5 years Risk-free interest rate 1.76-2.92% 1.27-1.95% Expected volatility 47-131% 86-109% Dividend yield 0 % 0 %
Schedule of Components of Changes in the Company’s Derivative Financial Instruments Liability Balance	The following table sets forth the components of changes in the Company’s derivative financial instruments — warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2017 Balance of derivative financial instruments — warrants liability 467,584 $ 649,387 Change in fair value of derivative financial instruments — warrants during the period recognized as a gain in the condensed consolidated statements of operations — (579,040 ) September 30, 2018 Balance of derivative financial instruments — warrants liability 467,584 $ 70,347

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Included in research and development expense $ 130,300 $ 219,480 $ 637,821 $ 798,143 Included in cost of revenue — 15,633 30,488 56,998 Included in selling, general and administrative expense 147,921 1,186,067 1,237,343 2,387,445 Benefit from restructuring — — — (125,222 ) Total stock-based compensation expense $ 278,221 $ 1,421,180 $ 1,905,652 $ 3,117,364
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards	The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated: Nine Months Ended September 30, 2018 2017 Risk-free interest rate 2.5 % 1.82 % Dividend yield 0 % 0 % Expected volatility 91 % 87 % Expected term 5.2 years 5.2 years
Summary of Stock Option Activity and of Changes in Stock Options Outstanding	A summary of stock option activity and changes in stock options outstanding is presented below: Total Options Weighted-Average Exercise Price Per Share Intrinsic Value Balance outstanding, December 31, 2017 374,251 $ 48.52 $ — Granted 316,744 $ 3.12 Canceled / Forfeited (189,540 ) $ 36.50 Expired (1,209 ) $ 36.00 Balance outstanding, September 30, 2018 500,246 $ 24.35 $ 3,370 Exercisable at September 30, 2018 355,696 $ 30.21 $ 1,950
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the RSU activity is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Share Intrinsic Value Non-vested RSUs outstanding, December 31, 2017 106,200 $ 17.22 $ 391,878 Granted 204,750 $ 0.77 Vested (77,572 ) $ 13.83 $ 268,151 Forfeited (18,506 ) $ 24.60 Non-vested RSUs outstanding, September 30, 2018 214,872 $ 2.14 $ 175,121
Summary of Warrant Activity and Changes in Warrants Outstanding	A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below: Total Warrants (1) Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (1) Balance outstanding, December 31, 2017 1,936,641 $ 11.34 4.4 Granted 20,700,000 $ 1.10 Exercised (447,108 ) $ 3.60 Balance outstanding, September 30, 2018 22,189,533 $ 1.94 4.6 (1) Excluded the pre-funded warrants to purchase 26,389 shares of common stock at a nominal exercise price of $0.12 per share. The pre-funded warrants were exercised in full during the nine months ended September 30, 2018 .

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details)	Jun. 01, 2018	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Oct. 31, 2018USD ($)shares	Dec. 31, 2017$ / shares
Subsequent Event [Line Items]
Common stock, par value (in USD per share) | $ / shares		$ 0.0001			$ 0.0001
Proceeds from exercise of warrants | $		$ 1,612,667	$ 0
Warrant exercised (in shares) | shares		447,108
Subsequent Event
Subsequent Event [Line Items]
Proceeds from exercise of warrants | $				$ 1,600,000
Common Stock
Subsequent Event [Line Items]
Stock split, ratio	0.0833
Common Stock | Subsequent Event
Subsequent Event [Line Items]
Warrant exercised (in shares) | shares				5,681,667

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Numerator:
Numerator: Net loss attributable to common shareholders	$ (3,775,628)	$ (4,298,026)	$ (15,090,413)	$ (22,355,494)
Adjustment for gain from change in fair value of derivative financial instruments—warrants	0	0	0	0
Net loss used for diluted loss per share	$ (3,775,628)	$ (4,298,026)	$ (15,090,413)	$ (22,355,494)
Denominator for basic and diluted net loss per share:
Weighted-average shares used to compute basic loss per share (in shares)	20,622,660	3,038,806	10,945,249	2,735,526
Adjustments to reflect assumed exercise of warrants (in shares)	0	0	0	0
Weighted-average shares used to compute diluted net loss per share (in shares)	20,622,660	3,038,806	10,945,249	2,735,526
Net loss per share attributable to common stockholders:
Net loss per common share - basic (in USD per share)	$ (0.18)	$ (1.41)	$ (1.38)	$ (8.17)
Net loss per common share - diluted (in USD per share)	$ (0.18)	$ (1.41)	$ (1.38)	$ (8.17)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	22,909,912	1,214,165
Stock Option
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	500,246	354,753
Warrants
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	22,189,533	747,709
Restricted Stock Units (RSUs)
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	214,872	106,442
Series A Preferred Stock | Convertible Preferred Stock
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	5,261	5,261

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Liabilities:
Derivative financial instruments—warrants	$ 70,347	$ 649,387
Estimate of Fair Value Measurement [Member] | Recurring basis
Assets:
Money market fund	14,974,256	8,309,964
Total Assets	14,974,256	8,309,964
Liabilities:
Derivative financial instruments—warrants	70,347	649,387
Total Liabilities	70,347	649,387
Estimate of Fair Value Measurement [Member] | Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Money market fund	14,974,256	8,309,964
Total Assets	14,974,256	8,309,964
Liabilities:
Derivative financial instruments—warrants	0	0
Total Liabilities	0	0
Estimate of Fair Value Measurement [Member] | Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Money market fund	0	0
Total Assets	0	0
Liabilities:
Derivative financial instruments—warrants	0	0
Total Liabilities	0	0
Estimate of Fair Value Measurement [Member] | Recurring basis | Significant Unobservable Inputs (Level 3)
Assets:
Money market fund	0	0
Total Assets	0	0
Liabilities:
Derivative financial instruments—warrants	70,347	649,387
Total Liabilities	$ 70,347	$ 649,387

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details) - Warrants	9 Months Ended
	Sep. 30, 2018USD ($)
Reconciliation of the beginning and ending balances
Balance at December 31, 2017	$ 649,387
Realized (gains) or losses	(579,040)
Balance at September 30, 2018	$ 70,347

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Property, equipment and depreciation and amortization
Property and equipment, gross	$ 3,979,610	$ 4,497,804
Less—accumulated depreciation and amortization	(2,352,005)	(2,071,492)
Property and equipment, net	1,627,605	2,426,312
Furniture and office equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	1,072,156	1,076,709
Leasehold improvements
Property, equipment and depreciation and amortization
Property and equipment, gross	1,994,514	1,994,514
Laboratory equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	$ 912,940	$ 1,426,581

Equipment Line of Credit (Detai

Equipment Line of Credit (Details) - Line of Credit - USD ($)	Apr. 06, 2018	Nov. 30, 2015	Sep. 30, 2018
Line of Credit Facility [Line Items]
Line of credit borrowing capacity (up to)		$ 2,000,000
Final payment of total amounts borrowed, percentage		7.00%
Repayments of debt	$ 1,100,000
Interest expenses recorded			$ 25,161
Prime Rate
Line of Credit Facility [Line Items]
Interest above base rate		1.25%

Derivative Financial Instrume_3

Derivative Financial Instruments - Warrants (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)			1,936,641
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	$ 2,500	$ (1,528,669)	$ (579,040)	$ (2,012,747)
Balance of warrants outstanding at the end of the period (in shares)	22,189,533		22,189,533
Balance of derivative financial instruments liability at the beginning of the period			$ 649,387
Balance of derivative financial instruments liability at the end of the period	$ 70,347		$ 70,347
Warrants | Black Scholes Option Pricing Method
Range of assumptions used to determine the fair value of warrants
Dividend yield (as a percent)			0.00%	0.00%
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)			467,584
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations			$ (579,040)
Balance of warrants outstanding at the end of the period (in shares)	467,584		467,584
Balance of derivative financial instruments liability at the beginning of the period			$ 649,387
Balance of derivative financial instruments liability at the end of the period	$ 70,347		$ 70,347
Warrants | Black Scholes Option Pricing Method | Minimum [Member]
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share)			$ 0.77	$ 8.76
Expected warrant term			3 months	1 year 3 months
Risk-free interest rate			1.76%	1.27%
Expected volatility (as a percent)			47.00%	86.00%
Warrants | Black Scholes Option Pricing Method | Maximum [Member]
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share)			$ 4.20	$ 15.12
Expected warrant term			5 years 1 month	5 years 6 months
Risk-free interest rate			2.92%	1.95%
Expected volatility (as a percent)			131.00%	109.00%

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($)	Jun. 12, 2018	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Class of Stock [Line Items]
Proceeds from sales of common stock and warrants, net of expenses of $1,336,123 and $575,516, respectively			$ 11,779,525	$ 6,634,803
Warrants granted (in shares)			20,700,000
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Restricted stock units issued during period (in shares)			77,572
Common Stock
Class of Stock [Line Items]
Shares of common stock issued (in shares)			18,557,893
Issuance of common stock upon exercise of warrants (in shares)			473,497
Exercise price of warrants (in USD per share)			$ 3.41
Shares issued upon conversion (in shares)	8,860,000		8,860,000
Stock Issued During Period, Shares, Conversion of Convertible Securities			8,860,000
Issuance of common stock for share rounding as a result of reverse stock split (in shares)			6,824
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities			8,860
Underwriting Public Offering
Class of Stock [Line Items]
Proceeds from sales of common stock and warrants, net of expenses of $1,336,123 and $575,516, respectively	$ 18,000,000
Warrants granted (in shares)	20,700,000	20,700,000
Exercise price of warrants (in USD per share)	$ 1.10
Underwriting Public Offering | Common Stock
Class of Stock [Line Items]
Shares of common stock issued (in shares)	9,140,000	9,140,000
Underwriting Public Offering | Series B Convertible Preferred Stock
Class of Stock [Line Items]
Shares of common stock issued (in shares)	8,860	8,860

Stockholders' Equity - Stock-ba

Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock-based compensation expense
Total stock based compensation expense	$ 278,221	$ 1,421,180	$ 1,905,652	$ 3,117,364
Options vested, fair value			1,515,946	3,378,243
Research and Development Expense
Stock-based compensation expense
Total stock based compensation expense	130,300	219,480	637,821	798,143
Cost of Revenue
Stock-based compensation expense
Total stock based compensation expense	0	15,633	30,488	56,998
Selling, general and administrative expense
Stock-based compensation expense
Total stock based compensation expense	147,921	1,186,067	1,237,343	2,387,445
Restructuring Charges
Stock-based compensation expense
Total stock based compensation expense	0	0	0	(125,222)
Stock Option
Stock-based compensation expense
Unrecognized compensation cost	$ 499,861	$ 3,271,046	$ 499,861	$ 3,271,046
Weighted-average remaining vesting period for recognition			1 year 3 months 18 days	2 years 2 months 23 days
Options outstanding, weighted average contractual life			7 years 7 months 5 days

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	May 30, 2018	May 29, 2018	Dec. 31, 2017
Stock Option
Weighted-average assumptions
Risk-free interest rate	2.50%	1.82%
Dividend yield (as a percent)	0.00%	0.00%
Expected volatility (as a percent)	91.00%	87.00%
Expected term	5 years 2 months 3 days	5 years 2 months
Number of Options
Balance outstanding at the beginning of the period (in shares)	374,251
Granted (in shares)	316,744
Cancelled / Forfeited (in shares)	(189,540)
Expired (in shares)	(1,209)
Balance outstanding at the end of the period (in shares)	500,246
Exercisable at the end of the period (in shares)	355,696
Weighted Average Exercise Price Per Share
Balance outstanding at the beginning of the period (in USD per share)	$ 48.52
Granted (in USD per share)	3.12
Canceled / Forfeited (in USD per share)	36.50
Expired (in USD per share)	36
Balance outstanding at the end of the period (in USD per share)	24.35
Exercisable at the end of the period (in USD per share)	$ 30.21
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Options outstanding, intrinsic value	$ 3,370				$ 0
Vested and exercisable at the end of the period, intrinsic value	$ 1,950
2014 EIP
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Authorized shares under the plan (in shares)			1,458,334	791,667
Number of remaining shares available for issuance (in shares)	637,798

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Units (Details) - Restricted Stock Units (RSUs) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Number of Shares
Non-vested at beginning of period (in shares)	106,200
Granted (in shares)	204,750
Vested (in shares)	(77,572)
Forfeited (in shares)	(18,506)
Non-vested at end of period (in shares)	214,872
Weighted-Average Grant Date Fair Value Per Share
Nonvested, weighted average grant date fair value at end of period (in USD per share)	$ 17.22
Granted, weighted average grant date fair value (in USD per share)	0.77	$ 19.08
Vested, weighted average grant date fair value (in USD per share)	13.83
Forfeited (in USD per share)	24.60
Nonvested, weighted average grant date fair value at end of period (in USD per share)	$ 2.14
Equity instruments other than options, aggregate intrinsic value, nonvested	$ 175,121		$ 391,878
Equity instruments other than options, aggregate intrinsic value, vested	268,151
Share-based compensation cost not yet recognized	$ 263,695	$ 1,011,494
Weighted-average remaining vesting period for recognition	2 years	2 years 5 months 16 days
Equity instruments other than options, vested in period, fair value	$ 1,072,714	$ 1,285,578

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Number of Warrants
Balance of warrants outstanding at the beginning of the period (in shares)	1,936,641
Granted (in shares)	20,700,000
Exercised (in shares)	(447,108)
Balance of warrants outstanding at the end of the period (in shares)	22,189,533	1,936,641
Weighted Average Exercise Price Per Share
Weighted average exercise price of warrants at the beginning of the period (in USD per share)	$ 11.34
Granted (in USD per share)	1.10
Exercised (in USD per share)	3.60
Weighted average exercise price of warrants at the end of the period (in USD per share)	$ 1.94	$ 11.34
Term
Weighted-Average Remaining Contractual Term	4 years 7 months 13 days	4 years 4 months 21 days
Pre-funded Warrant [Member] | Public Offering [Member]
Number of Warrants
Exercised (in shares)	(26,389)
Term
Exercise price of warrants (in USD per share)	$ 0.12

Stockholders' Equity - Series B

Stockholders' Equity - Series B Convertible Preferred Stock (Details) - USD ($)	Jun. 12, 2018	Jun. 30, 2018	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Class of Stock [Line Items]
Proceeds from sales of common stock and warrants, net of expenses of $1,336,123 and $575,516, respectively						$ 11,779,525	$ 6,634,803
Payments of stock issuance costs	$ 1,800,000
Warrants granted (in shares)						20,700,000
Preferred stock, par value (in USD per share)			$ 0.001			$ 0.001		$ 0.001
Deemed dividend recognized for beneficial conversion features of Series B Convertible Preferred Stock issuance			$ 0		$ 0	$ 2,769,533	$ 0
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Deemed dividend recognized for beneficial conversion features of Series B Convertible Preferred Stock issuance				$ 2,800,000
Preferred stock, shares outstanding (in shares)			0			0		0
Underwriting Public Offering
Class of Stock [Line Items]
Proceeds from sales of common stock and warrants, net of expenses of $1,336,123 and $575,516, respectively	$ 18,000,000
Warrants granted (in shares)	20,700,000	20,700,000
Exercise price of warrants (in USD per share)	$ 1.10
Over-Allotment Option
Class of Stock [Line Items]
Warrants granted (in shares)	2,700,000
Common Stock
Class of Stock [Line Items]
Shares of common stock issued (in shares)						18,557,893
Exercise price of warrants (in USD per share)			$ 3.41			$ 3.41
Shares issued upon conversion (in shares)	8,860,000		8,860,000			8,860,000
Common Stock | Underwriting Public Offering
Class of Stock [Line Items]
Shares of common stock issued (in shares)	9,140,000	9,140,000
Conversion ratio	$ 1
Common Stock | Underwriting Public Offering | Series B Convertible Preferred Stock
Class of Stock [Line Items]
Conversion ratio	$ 1,000
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Payments of stock issuance costs						$ (497,617)
Series B Convertible Preferred Stock | Underwriting Public Offering
Class of Stock [Line Items]
Shares of common stock issued (in shares)	8,860	8,860
Preferred stock, par value (in USD per share)	$ 1,000

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)ft²
Commitments and Contingencies Disclosure [Abstract]
Area under lease (in square feet) | ft²	26,100
Monthly rental rate | $	$ 73

Commitments and Contingencies -

Commitments and Contingencies - Research and Development Agreements (Details) - Nerviano - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Mar. 31, 2017	Sep. 30, 2018
Other Commitments [Line Items]
Other commitment		$ 1,000
Research and Development Arrangement | Research and Development Expense
Other Commitments [Line Items]
Research and development expense		$ 368
Licensing Agreements
Other Commitments [Line Items]
Research and development expense	$ 2,000

Restructuring Charges (Details)

Restructuring Charges (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges (benefit)	$ 421,351	$ (46,472)	$ 664,686	$ 1,669,526
Gain (loss) on disposal			52,000
Employee Severance
Restructuring Cost and Reserve [Line Items]
Restructuring charges (benefit)				1,200,000
Impaired Long-Lived Assets
Restructuring Cost and Reserve [Line Items]
Restructuring charges (benefit)			187,000	$ 500,000
Sublease
Restructuring Cost and Reserve [Line Items]
Restructuring charges (benefit)			$ 425,000

Subsequent Events (Details)

Subsequent Events (Details) $ in Thousands	Oct. 18, 2018USD ($)
Subsequent Event
Subsequent Event [Line Items]
Related party committed expenditures	$ 575